IsoFlow infusion catheter receives FDA marketing clearance

If you haven't seen this video about the IsoFlow infusion catheter, I think you'll be impressed. This is targeted drug delivery (not to be confused with targeted biologic drugs).

San Jose, Calif. – September 2, 2009 – Vascular Designs, a medical device company, today announced that its IsoFlow™ infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

The IsoFlow Infusion catheter enables sideways perfusion, which allows physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow’s unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. According to numerous studies, this approach lets physicians increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes when treating illnesses such as cancer with chemotherapy.

To read the entire press release, visit: Vascular Designs